A Randomized, Double-blind, Cross-over Study of S-600918 in Participants with Sleep Apnea Syndrome
- Conditions
- Sleep Apnea Syndrome
- Registration Number
- JPRN-jRCT2080225317
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
o obvious improvement in the primary endpoint of the change in AHI at Day 7 from baseline was found after administration of S-600918 300 mg compared with placebo, and the difference between the study drugs was not statistically significant. S-600918 was generally safe and well tolerated at a once daily dose of 300 mg for 7 days.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 33
Key Inclusion Criteria:
- Participants diagnosed with sleep apnea syndrome or suspected sleep apnea based on the International Classification of Sleep Disorders, Third Edition (ICSD-3).
Key Exclusion Criteria:
- Participants with a clinically significant active respiratory disease.
- Participants with obvious morphological abnormalities of the upper respiratory tract, micrognathia, or developmental failure of the mandible.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method